How Biopta has revolutionised human tissue studies
Dr Ruth McLaughlin, the clinical alliances manager at Biopta Ltd in Glasgow, explains how their new catalogue of preclinical human tissue assays is a first for the pharmaceutical industry and will help companies de-risk their clinical trials.
We recently announced a major development in discovery research with the launch of the first catalogue of assays based on human functional tissues.
Biopta assay catalogue
Want to access Biopta's catalogue of human functional tissue assays?
The catalogue will provide the scientific community with ready access to assays to help predict the safety, absorption and effectiveness of drug candidates in humans.
Studies using ethically-donated human tissues play a key part in drug development and provide pharmaceutical and biotechnology companies with a more predictive human model earlier in the development process. Many pharmaceutical and biotechnology companies have, up until now, depended solely on animal models, but giving them access to fresh functional human biomaterials means that early human tissue testing is increasingly becoming a routine part of preclinical drug discovery.
Our research has generated a database of over 60 assays in a range of human tissues. The database is the first library of human functional pharmacology using intact tissues outwith the body. By providing assays that accurately represent tissue characteristics and that measure drug responses from healthy and diseased human tissue, we’re helping fill a knowledge gap in preclinical testing.
Our catalogue aims to provide important human biology data during early stage drug discovery. The library is also a valuable searchable resource for experimenters seeking human translational research. We will continue to add tissue types, functional biomarkers of drug response and different mechanisms of drug action over the coming months.
More on life sciences in Scotland